Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.60 |
| ▸ | DDX3X | O00571 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004973 | 0.86 | MEN1 (0.71) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL11142985 | 0.83 | MAPT (0.67) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8752436 | 0.83 | SMN1; SMN2 (0.72) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5141415 | 0.82 | MEN1 (0.75) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL4186398 | 0.82 | HTT (0.62) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5213509 | 0.81 | CYP1A2 (0.78) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL30957465 | 0.81 | CYP1A2 (0.78) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL6159248 | 0.81 | MEN1 (0.80) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL27753743 | 0.81 | SMN1; SMN2 (0.60) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3217135 | 0.81 | MEN1 (0.64) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | PLK2, PDXK, PLK4 | HTT 2974/4885SMN1; SMN2 2774/4885MEN1 3222/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | HTT 3087/4885SMN1; SMN2 3196/4885MEN1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.